Our store location is now open with huge sales on RUO products. Monday, Wednesday and Friday 11 a.m. to 6 p.m., Saturday 11 a.m. to 4 p.m.
Marvel Peptide USA
SS-31 (Elamipretide)
SS-31

SS-31 (Elamipretide)

Supplied as a lyophilized powder in a sealed vial, for laboratory research use only.

from $25.00 per vial

Strengths and prices

StrengthPrice per vial AvailabilityBatch
10 mg $25.00 In stock SS-2607-0065
50 mg $75.00 In stock SS-2607-0063

Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.

What it is

SS-31 (elamipretide) is a synthetic tetrapeptide that enters cells and binds cardiolipin, a lipid of the inner mitochondrial membrane.

Identity

TypeSynthetic peptide, 4 amino acids
SequenceD-Arg-Dmt-Lys-Phe-NH2 (Dmt is 2',6'-dimethyltyrosine)
Molecular formulaC32H49N9O5
Molecular weight639.8 g/mol
CAS number736992-21-5
PubChem CID11764719

Elamipretide is a synthetic tetrapeptide, D-Arg-Dmt-Lys-Phe-NH2, in which Dmt is 2',6'-dimethyltyrosine, the first residue is the D-form of arginine and the C-terminus is amidated. The two unnatural residues distinguish it from a natural tetrapeptide and slow its breakdown by peptidases. With the N-terminal amine, the arginine and the lysine, it carries a net charge of +3 at neutral pH. Molecular formula C32H49N9O5, molecular weight 639.8 g/mol (PubChem CID 11764719, CAS 736992-21-5). Research material is often supplied as a salt, such as the acetate; the counterion adds to the weight of the powder but not to the peptide mass measured by mass spectrometry, while HPLC reports purity. It is supplied as a lyophilized powder in a sealed vial.

What the published research covers

Elamipretide has been studied in animal models of mitochondrial dysfunction and in clinical trials in Barth syndrome and primary mitochondrial myopathy.

SS-31 is one of a series of small aromatic-cationic peptides developed by Hazel Szeto and Peter Schiller, the two letters of its name. In 2004 the group reported that these peptides, built on alternating aromatic and basic residues with dimethyltyrosine, are cell-permeable and concentrate about 1,000-fold in the inner mitochondrial membrane. In neuronal N2A cells they reduced reactive oxygen species and cell death; in isolated mitochondria they inhibited swelling and cytochrome c release; and in an isolated heart model they improved contractile force after ischemia (Zhao, 2004). The compound was later developed clinically as elamipretide by Stealth BioTherapeutics.

In rats given SS-31 before renal ischemia, the peptide protected the cristae membranes of kidney mitochondria; using a fluorescent analogue, the authors reported that the peptide binds cardiolipin with high affinity and that the peptide-cardiolipin complex inhibits the peroxidase activity of cytochrome c (Birk, 2013). In aged mice, a single administration restored measures of skeletal muscle mitochondrial energetics, including ATP production and the phosphocreatine to ATP ratio, toward the levels of young mice within one hour, with no observed effect in young muscle, and eight days of administration increased whole-animal endurance (Siegel, 2013). In Barth syndrome, an inherited disorder of cardiolipin remodeling, a phase 2/3 crossover trial in 12 participants did not meet its primary endpoints, the six-minute walk test and a symptom scale, in its placebo-controlled part; in the open-label extension the authors reported improvements in both at 36 weeks (Reid Thompson, 2021). In primary mitochondrial myopathy, the phase 3 MMPOWER-3 trial randomized 218 participants and did not meet its primary endpoints on the six-minute walk test or the fatigue score at 24 weeks (Karaa, 2023).

The clinical picture is mixed. The placebo-controlled parts of both the Barth syndrome and the mitochondrial myopathy trials missed their primary endpoints, and the favorable Barth syndrome results come from an open-label extension in a small number of participants. The FDA's accelerated approval of elamipretide for Barth syndrome in September 2025 carries a requirement for a confirmatory trial (Zhao, 2026). Much of the preclinical literature comes from the developers and their collaborators, and results in rodent models of ischemia and aging do not establish an effect in people.

Regulatory status

Elamipretide received FDA accelerated approval in September 2025 as a prescription product for Barth syndrome. This material is not that product and is supplied for laboratory research only.

Testing and documentation

Identity is confirmed by mass spectrometry and purity by HPLC. The certificate of analysis for the batch is reachable from the code on the vial.

Questions laboratories ask

What strengths is SS-31 offered in?
Vials of 10 mg and 50 mg, as listed on the product page. The amount is on the vial label and on the certificate of analysis for the batch.
Is this the approved medicine?
No. Elamipretide received FDA accelerated approval in September 2025 as a prescription product for Barth syndrome, under the brand name Forzinity. This material is a research peptide of the same sequence, supplied for laboratory research only; it is not that product.
How is a batch tested?
By an independent laboratory: identity by mass spectrometry and purity by HPLC. The QR code on the vial opens the certificate of analysis for that exact batch; no account is needed to read it.
Who can order, and how does it ship?
Orders are accepted under the Research Use Agreement, reaffirmed with every order. Orders ship from Montana, the next business day when paid by card, to United States addresses only and not to freight forwarders.

References

  1. Zhao K et al. (2004). Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. The Journal of Biological Chemistry. PubMed 15178689
  2. Siegel MP et al. (2013). Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. PubMed 23692570
  3. Birk AV et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. PubMed 23813215
  4. Reid Thompson W et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine. PubMed 33077895
  5. Karaa A et al. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. PubMed 37268435
  6. Zhao C et al. (2026). Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval. Drug Discoveries & Therapeutics. PubMed 41260682

How it ships

Next day
Dispatched from Montana on all orders, packed and tracked.
One vial
The minimum order. You pay by card at checkout, or by invoice before the order ships.
Your batch
The certificate of analysis for the batch you receive is on the vial and on this site.

Ordering

Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.

Research use only

This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement

More from the catalog

All peptides, strengths and prices →